Investment Pitches

Pitch Summary:
Plaid's current valuation appears attractive due to its potential for quality growth, despite recent declines in net revenue retention (NRR) attributed to strategic shifts. The company is focusing on enterprise clients with higher growth potential, which could lead to significant revenue growth in the future.

BSD Analysis:
Plaid's recent NRR decline is primarily due to churn among small and medium-sized businesses (SMBs), which the company has consciously deprioritized in favor of enterprise clients. This strategic shift is expected to keep NRR weak until late 2025, after which it may recover as the effects of churn diminish and average revenue per user (ARPU) increases from recent price hikes. Despite the muted market reaction to recent earnings, the potential for 20–25% revenue growth in FY2026 and a significant EBIT increase suggests that Plaid could be a strong long-term investment. The company's focus on enterprise clients and the anticipated recovery in NRR could eventually lead to a re-rating of the stock.

Pitch Summary:
Hydreight Technologies has shown significant growth potential, particularly with its new vertical, VSDHone, which is a direct-to-consumer healthcare platform. The company has demonstrated strong growth in its existing verticals, Nurses and Stores, and is projecting substantial growth for VSDHone, which is expected to drive future revenue. The platform provides infrastructure for health and wellness companies to offer medical services online across the USA, with a unique ability to navigate the complex regulatory landscape. The company has already surpassed 2,000 daily orders, indicating strong market acceptance and execution capability. With a projected 1.3 million total orders for 2025, Hydreight is positioned to capitalize on the growing telehealth market.

BSD Analysis:
Hydreight's strategic positioning in the telehealth industry, particularly with its VSDHone platform, offers a significant competitive advantage. The platform's ability to provide comprehensive services, including telemedicine, pharmacy, compliance, and logistics, positions it as a critical enabler for other brands looking to enter the telehealth space. The company's growth trajectory is supported by its ability to execute on ambitious projections, as evidenced by its recent order growth. Furthermore, the telehealth industry is experiencing rapid growth, with a CAGR of 20-30%, providing a favorable market environment for Hydreight. The company's focus on self-administered telehealth services aligns with industry trends towards more personalized and accessible healthcare solutions.

Pitch Summary:
The author frames Netcompany as a solid but “pedestrian” grower in 2Q 2025 that has just executed a potentially transformative acquisition of SDC, a Nordic core-banking utility, for DKK 1 bn. SDC historically operated as a member-owned, cost-price provider to 100+ banks, which allowed Netcompany to buy a sticky, regulated revenue base at ~0.5× sales and ~3.5× EBITDA, considered very cheap. The plan is to maintain service quality while standardizing and productizing SDC’s offerings into modular platforms and then cross-sell Netcompany’s own digital solutions into that client base. Regulatory tailwinds from EU Instant Payments, DORA, PSD3 and related rules create mandatory spending and non-negotiable deadlines, and vendors already running core systems tend to be first in line to capture that spend. Management guides to 5–10% organic growth and 16–19% EBITDA margin for 2025, with SDC dilutive this year but accretive from 2026 and double-digit accretive by 2028, backed by ~DKK 6.2 bn of revenue visibility plus DKK 780 m from the new banking services unit. On current ttm multiples (EV/EBITDA ~13×, EV/Sales ~2×, P/E ~27×) and leverage of ~1.3× trending to 1.5×, the author sees scope for a re-rating as the low-multiple SDC asset is converted into a higher-margin platform. The core risk is that core banking is a trust-sensitive business: any major failure or loss of confidence could erase the thesis quickly. Overall, this is pitched as a “boring but exciting” European reg-tech/core-banking platform story with structural regulatory support and an under-monetised asset to convert.

BSD Analysis:
Strategically, Netcompany is executing a classic “buy the utility, sell the platform” playbook in a niche—Nordic core banking—where switching costs and regulatory complexity create high client stickiness. SDC brings a dense installed base and mission-critical workloads that, if successfully migrated to more standardized, modular offerings, can support software-like economics rather than utility-like margins. EU regulation is a real secular tailwind: initiatives like DORA and PSD3 effectively force banks to modernize infrastructure on fixed timelines, which tends to favour existing core vendors and reduces sales-cycle risk versus discretionary IT projects. However, integration and execution are non-trivial: Netcompany must avoid service disruption during migration, maintain trust with conservative banking clients, and carefully reprice offerings without triggering backlash from historically cost-sensitive customers. Financially, the group’s moderate leverage and ongoing buyback provide capital-structure flexibility, but also create pressure to deliver promised accretion from 2026 onward. If management can lift SDC’s margin profile toward Netcompany’s core business while cross-selling higher-value platforms, both mix and multiple should drift upwards, making the initial 0.5× sales entry look increasingly attractive over time. The key risks are operational (migration failures, outages), regulatory (unexpected requirements that strain delivery capacity), and competitive (larger core-banking players defending share). For a fundamental investor, this screens as a quality compounder with an embedded special-sits angle: a mispriced utility being converted into a scalable, higher-return software platform inside an already credible IT services franchise.

Actual Post Content:
2Q 2025 was pedestrian: revenue came in at DKK 1.7 bn with an adjusted EBITDA margin of 12.9%. Management held its full-year 2025 organic guidance steady at 5-10% growth with an EBITDA margin between 16% and 19%. On July 1, 2025, it completed its acquisition of SDC, a Nordic core-banking utility, for DKK 1 bn. SDC was folded into a new division, Netcompany Banking Services. The deal is dilutive to EPS in 2025, but to be accretive from 2026, and double-digit percent accretive by 2028. SDC was, historically, a member-owned, cost-price machine serving over 100 Nordic banks. $NETC.CO effectively bought a sticky, regulated revenue base at what appear to be very low entry multiples, around 0.5x sales and ~3.5x EBITDA based on 2023 figures. That is cheap. The task now is to make it not-cheap by (i) keeping service levels stable, (ii) standardizing and productizing SDC's offerings into modules, and (iii) cross-selling Netcompany’s own platforms into the newly acquired client base. The secular wind at their back is policy. A wave of EU regulations, including EU Instant Payments, Digital Operational Resilience Act, and Payment Services Directive 3 and Payment Services Regulation, creates non-negotiable deadlines for banks. Compliance doesn’t negotiate. And the vendors who already run a bank’s core systems tend to get the first call. Already $NETC.CO 's visibility is remarkably high, has ~ DKK 6.2 bn in revenue visibility for FY'25, plus 780m in contracted revenue from NBS. That’s a lot of dots already colored in. This is a conversion story disguised as an integration. SDC’s DNA meant its pricing had a cost-plus, please don’t yell at us" flavor. $NETC.CO 's plan is to hold service quality constant while standardizing, migrating, and selling modules at sensible software-like margins. Then the low entry multiple paid for SDC can start compounding into a group-wide re-rating, as markets recognize banks don't churn their core systems easily. $NETC.CO 's other digital platforms can turn the SDC utility into a true platform with attached, high-margin revenue. $NETC.CO Market cap: ~DKK 11.4bn; EV ~13.7bn. Multiples (ttm): EV/EBITDA ~13×, EV/Sales ~2×, P/E ~27×. Leverage~1.3× adj. EBITDA, trending to ~1.5× by YE’25. DKK 500m buyback live (to Jan’26). The upside is straightforward: a co-op utility bought at a low multiple becomes a productized platform, revenue mix improves, margins/multiples drift up. The downside is equally plain: core banking is a trust business. Lose that trust once, spreadsheets go out the window. And let's not forget. $NETC.CO operates in Europe where regulation is a growth industry. Boring can be exciting here. Do your own DD! Netcompany Group A/S"

URL: https://x.com/LaTranquillum/status/1963578417003061271

Pitch Summary:
The pitch frames Nordex as a “comeback” wind-turbine OEM that has restructured operations, focused on larger MW platforms, controlled costs, and built a healthy backlog — now reportedly €14.3 bn, which could cover roughly two years of revenue. The recent quarter showed a doubling of EBITDA margin (to 5.8%), order inflows up 82% YoY (2,310 MW), and a strong cash balance (~€942 m) with an equity ratio of 18%. A €3.1 bn service backlog — long-duration and >95% contractual — provides recurring, high-margin earnings less sensitive to macro swings. On a 2025e revenue of ~€7.4–7.9 bn and assuming a 5–7% EBITDA margin, the current EV/EBITDA of ~8× appears modest. The author argues that stripping out the service business suggests the project/turbine sales business is undervalued, implying significant latent value if service-related margin and backlog convert over time. With solid near-term earnings visibility and large backlog, modest improvements in cash flow or margin could lead to outsized upside.

BSD Analysis:
Nordex’s repositioning from historically volatile wind-OEM cycles to a model with a substantial service backlog and a diversified order book can create a more stable cash-flow foundation, reducing dependence on new turbine sales and the capricious nature of project cycles. The large backlog and recent margin improvement suggest improved operational execution and execution discipline — two critical differentiators in a sector where supply-chain disruption, regulatory shifts, and raw-material inflation have battered many peers. The service business provides a quasi-annuity stream with long duration and high margins, which should appeal to investors willing to treat this partly like a recurring-revenue industrial business rather than a pure capex cycle OEM. However, key risks remain: the wind energy industry is notoriously sensitive to changes in regulatory support — subsidies, tariffs, permitting rules — and potential policy reversal (especially in the U.S. or certain EU states) could quickly erode demand or delay projects. Additionally, 25% of the recent order book is reportedly “soft,” which introduces uncertainty — if macro conditions deteriorate or client financing fails, cancellations or renegotiations could materially impact revenue. Execution risk remains: delivering on backlog, managing supply chains, and converting service backlog into actual cash flow will be essential. Valuation at ~8× EV/EBITDA is compelling for a turnaround with leverage on backlog conversion, but investors must be prepared for volatility typical of wind-OEM cyclicality and regulatory dependence. For a patient, long-term investor with conviction in renewable energy policy durability, Nordex offers a potentially asymmetric return — but only if execution and macro-policy remain aligned.

Actual Post Content:
Nordex SE $NDX1.DE is a post-turnaround, onshore wind turbines company. Q2 results show profitability, order growth, and a cash-rich balance sheet. Wind is a weird, complicated sector: essential to net zero, volatility-ridden, policy-sensitive. European wind OEMs have been serial value destroyers. Why? Structural margin compression, supply chain messes, regulatory whimsy. Nordex, however, is emerging as the “comeback kid”: from pivoting to bigger MW platforms, cost discipline, and now €14.3 bn backlog, enough orders to cover almost two years of forward revenue. Moreover, Nordex in 2Q printed an EBITDA margin of 5.8%, nearly doubling YoY. Order inflow is turbo-charged, 2,310 MW booked, up 82% YoY, with average project size increasing. The cash story? €942m, equity ratio 18%. This isn’t a company skating on thin ice anymore. Of €14.3 bn backlog, Service backlog is ~€3.1bn, >95% contractual, 10-15yr duration. Risk always lurks in regulatory regimes (will EU green industry subsidies really materialize, or just help incumbent utilities?) Meanwhile, US policy has become more erratic. Let’s not mince words: the past teaches us wind OEMs “earnings visibility” can disappear fast, project delays, outright cancellations, and sudden procurement freezes litter history. 25% of Q2’s order book may be “soft,” i.e., subject to delay or renegotiation if macro turns. Valuation: Revenue 2025e (as guided): €7.4-7.9 bn; EBITDA margin (as guided): 5.0-7.0%; EV: €4.16 bn; EV/EBITDA: ~8x; Net operating loss carry-forwards ~€0.8 bn. High operational leverage + low EV/Sales creates classic “turnaround LBO” profile once equity ratio > 25%. If Nordex were a private asset with €7.5 bn sales, 6% mid-cycle EBITDA, net cash, growing service annuity and a double-digit order book multiple, would €3.5 bn EV be cheap? PE comps typically pay 0.7–0.9 × sales for similar asset intensity; hence fair EV ≈ €5.5–6.5 bn. Next, special sits angle: The service arm, using standard multiples of 10×, is worth an estimated €2.3 bn in EV. Implying that, the projects business (which includes turbine sales and installations) is effectively being valued at less than 0.2× sales, a deep value multiple. Parent Acciona (33% stake) has historically been unwilling to bid for full control, but could act as a put floor in stress scenarios. Its vested interest could lead to supportive action (i.e, through strategic backup, or acting as a white knight in sale scenarios). With robust near-term earnings visibility, NDX1.DE has its eyes set on high-margin, service-focused strategy, backed by solid backlog, a proven ability to generate cash flow. Modest improvements in margin/cash conversion could spark outsized gains.

URL: https://x.com/skewangles/status/1963538561203888274

Pitch Summary:
Info-Tech Systems is Singapore’s leading SME-focused HRMS SaaS provider, offering mission-critical payroll, HR, and compliance software with a growing accounting and services ecosystem. The company generates predominantly recurring revenue with high gross margins and strong cash conversion, reflecting a capital-light and durable business model. After a soft H1 2025 result, the stock has fallen below its IPO price as investors extrapolate near-term growth weakness in its mature home market. This has overshadowed continued improvements in customer retention and a successful expansion into Malaysia, where growth has compounded at a materially higher rate. At current levels, valuation implies a pessimistic growth outlook despite high EBIT margins, strong ROE, and a net cash balance. Even modest growth normalization would support intrinsic value above the current share price. Key risks include slower regional expansion or increased competition, but downside appears supported by free cash flow generation.

BSD Analysis:
Info-Tech is being priced as a structurally challenged small-cap SaaS rather than a high-quality, cash-generative platform experiencing a temporary growth pause. The market’s variant perception anchors on post-IPO disappointment and near-term softness, ignoring improving retention, deep compliance localization, and strong capital efficiency. Business quality is unusually high for a company of this size, with ~85% gross margins, ~37% EBIT margins, and exceptional EBITDA-to-cash conversion. What the market is missing is the durability of SME switching costs in payroll and compliance, where local expertise and hands-on support create meaningful barriers to global incumbents. Malaysia expansion is underappreciated, having been achieved with declining marketing intensity, signaling strong product-market fit and organic adoption. Valuation at single-digit EV/FCF embeds little credit for optional growth or strategic value. With founder ownership high and balance-sheet risk minimal, even modest re-acceleration in growth could drive a meaningful re-rating.

Pitch Summary:
Medexus is a North American specialty pharma company at a major earnings inflection following long-delayed FDA approval of Treosulfan (Grafapex in the U.S.). The legacy portfolio (Ixinity, Rasuvo, Rupall) is mature and slightly declining but remains cash generative, trading at ~3–4x EV/EBITDA on a standalone basis. The market is largely ignoring Grafapex, a conditioning regimen for stem cell transplants that management expects to become a ~$100M+ high-margin product within five years and potentially the new standard of care versus Busulfan. As Grafapex ramps, the company’s revenue mix shifts toward ~80% gross margins, driving EBITDA inflection and substantial free cash flow generation. At current prices, MEDXF trades at a fraction of peer multiples and approaches ~1–1.2x EV/2029 EBITDA under conservative assumptions, with meaningful upside if adoption mirrors Europe.

BSD Analysis:
Medexus is priced as a declining specialty pharma despite having just unlocked a transformational growth asset. The base business alone supports much of today’s valuation, yet the market assigns minimal value to Grafapex because revenues have not yet appeared in reported financials. As Grafapex commercialization shows up in quarterly numbers, margins expand and EBITDA compounds rapidly, forcing a rerating toward peer multiples. Execution risk exists given past FDA delays, but valuation already discounts substantial disappointment. The setup reflects classic catalyst lag: regulatory risk is gone, economics are strong, but the stock still trades as if approval never happened.

Pitch Summary:
Calumet is a specialty products and renewable fuels company with two distinct businesses: a cash-generative core specialty segment and the Montana Renewables (MRL) renewable diesel and SAF platform. After a bruising 18 months marked by weak renewable margins and balance sheet concerns, the stock has fallen out of favor despite improving fundamentals. The core specialty business is currently operating at above mid-cycle conditions and is capable of generating meaningful free cash flow that supports much of the current equity value. MRL sits low on the renewable fuels cost curve and is nearing a major inflection as SAF production ramps toward 130–150 million gallons with offtake visibility improving. The market is effectively assigning little to no value to MRL due to skepticism around renewable margins and leverage. Near-term catalysts include SAF offtake announcements, evidence of margin recovery in renewable fuels, and balance sheet deleveraging via asset sales and free cash flow. The setup offers asymmetric upside if earnings power inflects while downside is partially protected by the core business cash generation.

BSD Analysis:
Calumet is being valued as a structurally broken renewables story rather than a cash-generative specialty refiner with a deeply out-of-the-money but increasingly credible SAF call option. The market’s core blind spot is treating Montana Renewables as permanently impaired, despite its advantaged cost position and the visibility emerging around SAF volumes that could meaningfully reframe earnings power. The specialty segment quietly underwrites much of the current equity value, providing real downside protection while deleveraging progresses. Business quality is asymmetric: steady specialty cash flows coexist with a policy-backed growth asset that does not need heroic margins to matter at today’s valuation. The balance sheet remains leveraged, but incremental improvements in cash flow can drive rapid equity torque given how low expectations are embedded. Valuation today reflects survival math rather than normalized earnings power, creating a sharp convexity if renewables margins recover even modestly. This is best sized as an inflection trade where sentiment, not asset quality, is the primary overhang.

Pitch Summary:
FinVolution is a China-based, asset-light consumer credit facilitator that matches online borrowers with >100 institutional partners and monetizes via facilitation/servicing fees. Since pivoting away from P2P in 2021, it has delivered uninterrupted YoY growth despite COVID and regulatory resets, with H1’25 revenue +11.5% and operating income +43%. Roughly 80% of revenue remains China, but international (Indonesia/Philippines, with Pakistan next) is ~20% and compounding ~70%+, with a 2030 mix goal of 50% ex-China. The model’s risk profile is improving: ~50% of balances are now capital-light, revenue is >50% fees, and risk-bearing leverage has fallen to ~2.6x equity. ROE has averaged ~30% since 2017 (now high teens) and repeat borrowers drive >85% of volume, supporting unit economics. Capital returns are robust: ~$830mm returned since IPO (dividends/buybacks), a 20–30% payout target, and a stated commitment to a rising dividend. Management guides 10–15% revenue growth for 2025, with street implying double-digit EPS CAGR into 2027. Key risks are regulatory (China/Indonesia), macro credit cycles, and ADR/VIE structure, but the company has repeatedly adapted to rule changes. On ~4.9x/4.4x ’25/’26 P/E and ~2x TEV/EBIT, the stock embeds a steep China/VIE discount. A 9x NTM EPS framework yields ~$14.76 fair value (~90% upside) as mix shifts abroad and toward capital-light fees.

BSD Analysis:
The crux is whether FINV can keep compounding while diluting China-specific risk. Two parallel shifts argue yes: (1) geographic—international is earlier-stage with less regulatory overhang and faster TAM growth; (2) economic—capital-light fee income expands margins and compresses tail risk versus balance-sheet lending. If management sustains double-digit loan facilitation growth with stable delinquency and keeps risk-bearing leverage drifting lower, multiple mean-reversion toward high single-digit P/E is plausible even without China re-rating. Watch for signals: international take-rate/credit performance, the October China rule implementation vs. guidance, and payout discipline in the face of volatility. A credible path to 50% international mix plus 60–70% capital-light revenue would structurally lift ROIC and shrink downside tails; conversely, a sharp regulatory cap or liquidity squeeze in China could overwhelm diversification. Sizing should reflect VIE/sovereign risk, but the asymmetry looks favorable given valuation, cash, and shareholder-friendly capital returns.

Pitch Summary:
Calumet offers asymmetric upside as the market gives little to no value to Montana Renewables (MRL) while the core specialty business supports much of the current equity. The core segment is running above mid-cycle and, pro forma for deleveraging, is on a path to $125–$150mm FCF (~$1.50/share), providing downside support. Bears argue renewable diesel/SAF margins won’t recover and leverage is too high, but near-term catalysts can flip sentiment. First, MRL expects to place 130–150mm gallons of SAF via offtake agreements, which should validate volumes and premium realization. Second, policy/market mechanics (RVO finalization, SRE reallocation, foreign feed treatment, RINs supply) point to index margin improvement into 2026. Third, asset sales plus core FCF should drive $300mm+ near-term deleveraging, reducing balance-sheet overhang. Management targets all-in MRL opex of ~$0.40–$0.45/gal and a SAF-heavy slate by early 2026, positioning MRL on the low end of the cost curve. In a downside with only SAF offtake clarity, MRL earnings power could be ~$250mm in 2026; with margin recovery, $425–$525mm is plausible. SOTP suggests $20–$30/share of value from MRL alone, with scenarios to $40–$50 if Phase 2 growth is recognized, on top of core value.

BSD Analysis:
Two engines: (1) Core specialty products/refining generating resilient FCF near/above mid-cycle; (2) Montana Renewables (MRL) focused on renewable diesel and especially SAF. Set-up: Stock fell on renewable margin collapse and DOE-loan/SAF skepticism; today’s price implies minimal value for MRL while core FCF underpins equity. Deleveraging: Expected $300mm+ via asset sale and organic FCF near term; taking out 2026 notes and chipping at 2027s should tighten the equity story. MRL economics: Low-cost operator targeting ~$0.40–$0.45/gal opex; 130–150mm gal SAF ramp early 2026 with offtake visibility; limited capex needs and attractive FCF conversion. Policy tailwinds: RVO uplift, SRE reallocation, tighter RINs balance, and constraints on foreign feedstocks steepen the cost curve and support index margins into 2026–27. Valuation: Market bakes in Street’s ~$370mm 2026 EBITDA; author sees $550mm base case and up to $700mm with margin normalization, implying $35–$55/share scenarios from SOTP and multiple re-rating. Risks: Renewable margins stay depressed, delays in SAF offtakes, execution at MRL, slower or smaller asset sales, and policy slippage.

Pitch Summary:
Medexus is a North American specialty pharma company positioned for a major earnings inflection following U.S. FDA approval of Treosulfan (Grafapex). The base business—anchored by Ixinity, Rasuvo, and Rupall—generates roughly $100M in annual revenue and $17M in EBITDA at low- to mid-50% gross margins. While Ixinity and Rasuvo remain stable low-growth assets, Rupall faces generic erosion following its 2025 patent expiry. The recent pediatric indication for Ixinity should provide incremental volume, offsetting some headwinds. The transformative catalyst is Treosulfan’s launch, expected to replace Busulfan as the U.S. standard of care for stem cell conditioning. Management guides for $100M in high-margin Grafapex sales within five years, potentially lifting group EBITDA to $65M by 2029. Shares currently trade near 4.6x LTM EV/EBITDA and roughly 1.2x EV/2029E EBITDA. A re-rating to 6–8x 2029E EBITDA implies >6x upside. Execution on Grafapex commercialization represents a near-term catalyst and value unlock.

BSD Analysis:
Medexus markets specialty pharmaceuticals across North America, led by Ixinity (Hemophilia B), Rasuvo (rheumatoid arthritis), Rupall (antihistamine), and Treosulfan (Grafapex) for AML/MDS transplant conditioning. Thesis: The Grafapex approval unlocks a $100M+ U.S. opportunity at ~80% gross margins, transforming profitability and FCF generation. Valuation: EV ~$80M vs. $17M LTM EBITDA implies 4.6x multiple; on 2029E $65M EBITDA, valuation compresses to ~1.2x. Applying a conservative 7x multiple yields ~$540M market cap or $13.77/share. Set-up: Stock is overlooked due to Canadian listing, small cap, and long regulatory delays; financials have yet to reflect Grafapex revenue. Risks: Execution on U.S. launch, FDA/tariff policy changes, base drug erosion (Rupall generics, Ixinity demand), and historical capital allocation missteps. View: Deep value, strong margin uplift, and near-term catalysts position Medexus for a multi-bagger re-rate.